Houbin Sun1, Minghui Zhang2, Ruibao Liu1, Yan Liu1, Yingwen Hou1, Changjun Wu3. 1. Department of Interventional Radiology, The Cancer Hospital of Harbin Medical University, Harbin, 150040, PR China. 2. Department of Medical Oncology, The Cancer Hospital of Harbin Medical University, Harbin, 150040, PR China. 3. Department of Imaging & Nuclear Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, PR China.
Abstract
AIM: The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of 125I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). PATIENTS & METHODS: The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015. RESULTS & CONCLUSION: Compared with the TACE treatment alone, the combination therapy of 125I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCC patients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCC patients with PVTT.
AIM: The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of 125I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). PATIENTS & METHODS: The study included 134 pathologically proven or clinically confirmed primary HCCpatients with PVTT in our hospital from January 2013 to June 2015. RESULTS & CONCLUSION: Compared with the TACE treatment alone, the combination therapy of 125I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCCpatients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCCpatients with PVTT.